A Novel Multicompartment Barrier‐Free Microfluidic Device Reveals the Impact of Extracellular Matrix Stiffening and Temozolomide on Immune‐Tumor Interactions in Glioblastoma
Small · 2025-03 · 21 (9)
DOI: 10.1002/smll.202409229 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 03.02.2025. Verfasst von Clara Bayona und 8 weiteren Autor:innen. Beteiligte Einrichtung: Tissue Microenvironment (TME) Lab, Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, 50018, Spain. Hauptthemen laut MEDLINE: Glioblastoma, Temozolomide, Extracellular Matrix, Lab-On-A-Chip Devices. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gobierno de Aragón, Ministerio de Economía y Competitividad, Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
The immune system plays a crucial role in shaping the glioblastoma tumor microenvironment, characterized by its complexity and dynamic interactions. Understanding the tumor‐immune crosstalk is essential for advancing cancer research and therapeutic development. Here, a novel multicompartment, barrier‐free microfluidic device is presented that overcomes the limitations of existing models by enabling direct tumor‐immune interactions without physical barriers, preserving natural immune cell infiltration. This platform supports the independent and simultaneous culture of tumor and immune cells, replicating the healthy‐tumoral stroma interface, and allows investigating the effect of matrix stiffness and chemotherapy on both populations. The findings reveal that increased collagen concentration promotes tumor invasiveness while impairing immune cell infiltration. Additionally, temozolomide treatment reduces immune cell motility but enhances anti‐tumor immune responses. These insights highlight the critical roles of extracellular matrix mechanics and chemotherapy in tumor progression and immune modulation, establishing this device as a powerful tool for studying glioblastoma‐immune dynamics and evaluating therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tissue Microenvironment (TME) Lab, Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, 50018, Spain.
- Institute for Health Research Aragón (IIS Aragón), Zaragoza, 50009, Spain.
- BEOnChip S.L., Zaragoza, 50018, Spain.
- Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, 28029, Spain.
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-University of Zaragoza, Department of Organic Chemistry, Zaragoza, 50009, Spain.
ORCID-Profile: Clara Bayona, Claudia Olaizola-Rodrigo, Mehran Ashrafi, Manuel Doblaré, Ignacio Ochoa, Sara Oliván
Förderung
- Gobierno de Aragón
- Ministerio de Economía y Competitividad
- Ministerio de Ciencia e Innovación
- European Regional Development Fund
- Chips Joint Undertaking
Zitieren
APA
Bayona, C., Olaizola-Rodrigo, C., Sharko, V., Ashrafi, M., Barrio, J. D., Doblaré, M., Monge, R., Ochoa, I., & Oliván, S. (2025). A Novel Multicompartment Barrier‐Free Microfluidic Device Reveals the Impact of Extracellular Matrix Stiffening and Temozolomide on Immune‐Tumor Interactions in Glioblastoma. Small, 21(9). https://doi.org/10.1002/smll.202409229
Vancouver
Bayona C, Olaizola-Rodrigo C, Sharko V, Ashrafi M, Barrio JD, Doblaré M, et al. A Novel Multicompartment Barrier‐Free Microfluidic Device Reveals the Impact of Extracellular Matrix Stiffening and Temozolomide on Immune‐Tumor Interactions in Glioblastoma. Small. 2025;21(9). doi:10.1002/smll.202409229
BibTeX
@article{Bayona2025,
author = {Bayona, Clara and Olaizola-Rodrigo, Claudia and Sharko, Vira and Ashrafi, Mehran and Barrio, Jesús Del and Doblaré, Manuel and Monge, Rosa and Ochoa, Ignacio and Oliván, Sara},
title = {A Novel Multicompartment Barrier‐Free Microfluidic Device Reveals the Impact of Extracellular Matrix Stiffening and Temozolomide on Immune‐Tumor Interactions in Glioblastoma},
journal = {Small},
year = {2025},
volume = {21},
number = {9},
doi = {10.1002/smll.202409229}
}
EUVIMED